Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and, since founding Design Portfolio in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also Chairman of Flathill Communications Group plc, President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society.

Mette has broad international experience within biotech and life sciences both as an investor, as a board member, and operationally, covering business development and licensing, management and financing. 

Mette has been appointed to numerous board positions in both private and public companies in Europe and the US. She currently has six board positions in the US and Europe.

Mette previously founded and managed Lundbeckfonden Ventures, completing around 40 European and US investments over a 12 year period, and was part of the management at the Lundbeck Foundation. Before that, she was co-founder and CEO of 7TM Pharma A/S. She started her biotech career as part of the management team of NeuroSearch A/S, responsible for business development and licensing.

Mette started as a patent agent and, over the years, has co-founded several biotech companies. Mette graduated as a biologist from the University of Copenhagen and has an MBA from Henley Business School.

Renée is CEO of Calliditas Therapeutics AB and was previously a Partner and COO of Omega Funds. Before Omega, she served as a Partner in the Venture Capital group 3i Group plc in London where, since 2005, she was responsible for managing its publicly quoted assets and European legacy healthcare portfolio. Prior to this, she was a European Group Head and MD in investment banking. Renée has over twelve years of corporate finance experience with firms such as BT Alex Brown, Deutsche Bank and Lehman Brothers, where she focused on raising M&A and private and public capital for growth companies in both Europe and the US. Prior to investment banking, Renée worked for five years in European sales and marketing for a financial services-focused software business. Renée has a BA in Finance from Stockholm School of Economics and an MBA from INSEAD. She has significant Board experience from both private and public US and European Board work.

Vadim leads the Healthcare Team at SP Angel, after having established a strong reputation for supporting growing and developing healthcare companies in the UK. Prior to joining SP Angel in 2019, he led the research team at Northland Capital Partners, where he established a Healthcare sector franchise from a standstill and turned it into the company’s highest revenue generating sector. Vadim also held roles at Daniel Stewart & Company, achieving a top Hemscott ranking, as well as other healthcare analysis roles in Montreal, Canada. 

Georgia has held business development and corporate development positions within specialist Life Sciences consultancies, including Investor Relations and Executive search across the US and Europe, for the last ten years. Georgia joined LifeSci two years ago, with a primary focus on LifeSci’s Investor Relations business. Georgia now represents the whole LifeSci Platform which includes LifeSci Advisors (IR), LifeSci Consulting, LifeSci Capital (investment bank), LifeSci Venture, LifeSci Communications, First Thought (KOL network), LifeSci Search (board & executive search) and LifeSci Associates (on-demand-talent).

Nigel is a Partner at the Specialist Life Science Investment Bank, WG Partners. Nigel has more than 35 years experience of working in the Life Science sector. He has a PhD in Pharmacology and has previously worked in the Pharmaceutical industry in both Research and Sales & Marketing. He moved into the City as an Equity Research Analyst in 1986 working for Hoare Govett and then Merrill Lynch from 1994 until 2005. He was a Founding Partner of Sudbrook Associates, a Corporate Advisory business with a Private Equity focus. He then joined WG Partners in 2012, shortly after the business was founded. He is a NED of a private biotech business, Avipero Limited. He is also a member of the External Commercialisation Board at the School of Medicine and Dental Sciences, University of Birmingham where he also holds a Honorary Senior Lectureship at the Medical School. He is also a member of the 'Honorary Advisory Committee' at The Art Academy London.

Julia joined FTI Consulting’s life sciences team in February after a 15-year career in journalism. Before joining FTI she spent seven years working as a senior journalist and editor on the business pages of The Daily Telegraph, specialising in pharma and biotech. 

Victoria joined J.P. Morgan Asset Management in the European Research team covering the healthcare sector more than ten years ago. She also contributes to the J.P. Morgan Global Healthcare Fund. She became a CFA Charterholder in 2009 and has a BSc in Chemistry from Durham University.

John Dawson joined Oxford BioMedica’s Board as Non-Executive Director in August 2008 and he was appointed Chief Executive Officer in October 2008. Previously, he held senior management positions in the European operations of Cephalon Inc., including Chief Financial Officer and Head of Business Development Europe. While at Cephalon he led many deals building the European business to over 1,000 people, and to a turnover of several hundred million US dollars and in 2005 led the US$360 million acquisition of Zeneus by Cephalon. Prior to this time at Cephalon he was Director of Finance and Administration of Serono Laboratories (UK) Limited.

Stefan is a Director of Equity Research in the Healthcare and Life Sciences team at Numis, which is currently the No.1 Extel (2019) ranked team in the UK sector. The Numis team provides broad coverage of over 30 UK-listed mid and small-cap healthcare and life sciences companies and acts as broker or adviser to around 20 listed and private companies in the sector. Stefan has over 20 years of City experience as an analyst and in strategy consulting and has helped to raise over £2bn for healthcare and life sciences companies. He has a PhD in biochemistry from the University of Cambridge and is a CFA charterholder. 

Nooman is Head of life sciences and healthcare for EMEA at Silicon Valley Bank. He leads a team focused on supporting innovative and high growth companies with banking and financing solutions. Previously he was head of direct investments at a sovereign wealth fund and has also worked in Government as an economic advisor.

Anne has been Managing Partner of MC Services since 2011 and has over 20 years of experience in Financial and Strategic Communications. She was responsible for setting up the MC Services office in Düsseldorf and building the team and operations there. Prior to that, she held senior management positions in international pharma and biotech companies. She headed the Investor Relations and Corporate Communications department of Evotec AG for 10 years and was a member of the company’s Executive Committee. Previously, she was responsible for Investor Relations and Corporate Communications at Schwarz Pharma AG, where she initially held management positions in the International Marketing department. During her career she managed Evotec’s IPO on the Frankfurt Stock Exchange and Nasdaq, multiple M&A programs and major financial transactions. Anne is a pharmacist and marketing expert by training. Her sector expertise includes pharma and life sciences with experience in all major indication areas.

Max joined Stifel in September 2013 as Head of European Healthcare Equity Research. Prior to joining Stifel, Max was Chief Financial Officer of Silence Therapeutics plc. He possesses more than 25 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development-stage companies, as well as establishing several highly rated equity research teams at a number of investment banks. He has also been involved in raising over $1bn for biotech companies. 

Max holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Accountant with Arthur Andersen.

Uli is a Managing Director at goetzpartners. He is responsible for the Industry Group Healthcare. He is a founding partner of Code Securities Limited, a specialist life science investment bank which was formed in 2003, acquired by Nomura in 2005 and continued as Nomura Code Securities until late 2013. As Director, Corporate Finance, Ulrich Kinzel was instrumental for building the continental European M&A and Equity Capital Markets business. He was previously a Director of WestLB Panmure’s Life Science Team. He has advised leading international live science companies in more than 50 successful M&A and ECM transactions, including cross-border European, Asian and US public and private takeovers as well as IPOs and secondary off erings on all major European Stock Exchanges. He holds a master’s degree in Business Administration from Munich University.

Matthew has over a decade of international financial and corporate communications experience at City PR firms and since joining Consilium Strategic Communications as a founding member, he has specialised in healthcare. He has advised both listed and private clients on strategic financial communications strategies across all subsectors of healthcare, as well as providing advice on crisis communications, capital market transactions, IPOs and M&A. Matthew speaks fluent Italian and Polish.

We are delighted to welcome Rose to the Voting Panel and her details will be available in due course. 

Nick is an experienced Non-executive Director and Chairman with a background as a successful corporate financier. He has considerable experience of businesses in the Healthcare, Medical, Biotechnology, Environmental and Technology sectors. Nick is Chairman of Destiny Pharma plc, an anti-infectives drug developer. He is also chairman of SEHTA, one of the largest health technology networking organisations in the UK and a part-time Director of Alcuris, an emerging Telecare and Telehealth business. Until 2016, Nick was Chairman of Oxford BioMedica plc, a leading gene-based biopharmaceutical company and, through Ipso Ventures, he helped found Therakind, a developer of paediatric medicines. 

Sachin is the co-founder and Fund Manager of Third Eye Healthcare Fund. Third Eye is an open ended long-biased long/short global healthcare investment fund. The Fund’s objective is to generate long-term returns for investors by investing in carefully selected publicly listed healthcare companies. The Fund’s performance should come primarily from long positions, with short positions providing protection in the event of market corrections. The Fund maintains up to 50% exposure to European Healthcare. Prior to incorporating Third Eye in 2016, Sachin worked as Director and Head of the Life Sciences team in the securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands. During his eight years at Kempen & Co from 2008 to 2016, he led a team of five, was responsible for coverage of the European Healthcare and Life Sciences sector and won Extel and StarMine awards for stock picking. He has over fifteen years of experience in life sciences, with an exposure to both private (Venture Capital) as well as public market investments, and has been involved in multiple IPOs and secondary transactions, raising over €1.0bn for various life sciences companies.

Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 20 years’ experience in life sciences research, covering both UK and continental European companies across a wide range of healthcare subsectors. Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early-stage medical technologies.

Ivo currently heads up the Public Equity team at HBM Partners. This company was founded in 2001, with the goal to invest in private and public emerging biopharma and other healthcare-related companies. HBM Partners manages and advises several investment companies and funds, the best-known of which is HBM Healthcare Investments. Ivo joined HBM Partners in 2003 as Investment Advisor for the Biotechnology and Pharma sector. Prior to that, Ivo worked as a Biotechnology Analyst at Bank Sarasin, and before that was Department Head at MDS Pharma Services, Switzerland. Ivo studied chemistry at the University of Groningen, the Netherlands, and was a visiting scholar at the Department of Biology at MIT in 1991. He obtained his PhD in Biology from the ETH in Zurich, Switzerland, in 1996. He has over 18 years’ experience in investment management and research, and is a CFA Charter Holder since 2004.

Melanie is a Partner, Life Sciences, at Instinctif and she leads on financial communications within the Life Sciences team. She has 20 years of experience advising life sciences companies on financial communications. Prior to joining Instinctif, she built and established the life sciences practice at the Hogarth Partnership. She was a Partner in the Financial Dynamics (now FTI) Life Sciences team and a Director at Merlin Financial PR. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare industries, as well as advising specialist VC and IP commercialisation companies. Before entering business communications, she was at Price Waterhouse, where she qualified as a Chartered Accountant. She has a BA in Biochemistry from the University of Oxford.

Dylan started his career in Lifesciences Equity Research six years ago at various boutique investment banks in the Netherlands, and has covered the European MedTech and Biotech sector for Bryan Garnier & Co in Paris and most recently in London as head of the Healthcare Equity Research team. His experience ranges from research on public and private companies to fundraising activities. Dylan has a degree in Business and Finance from the university of Amsterdam.